Researchers presented that the intravenous administration of the potent signal transducer and activator of transcription 3 (STAT3) inhibitor (WP-1066)-loaded liposomes in combination with in vivo dendritic cell-targeted genetic immunization is effective as an anti-GBM treatment. The gene discussed is STAT3; the disease is glioblastoma.